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Abstract The relationship between a tumor cell and its
microenvironment is bi-directional. The proteins expressed
by the tumor cells alter the signatures on the seemingly
normal stromal cells within the microenvironment, while
the tumor cell signatures reflect the changes that occur as
these cells interact with the host microenvironment.
Galectin-3 is a carbohydrate-binding protein that is over-
expressed in a variety of tumors and immune cells in
response to various stimuli. Ever since its discovery, it has
been associated with cell and extracellular matrix inter-
actions. However, in the last decade, an extensive accumu-
lation of data has changed the perspective of this
multifunctional protein. The unique structure of this
protein, consisting of a carbohydrate-binding domain and
a matrix metalloproteinase cleavable domain, enables it to
interact with a plethora of ligands in a carbohydrate-
dependent or independent manner. It is now becoming
evident that galectin-3 is involved with a variety of
extracellular functions like cell adhesion, migration, inva-
sion, angiogenesis, immune functions, apoptosis and
endocytosis. Galectin-3 is a substrate for matrix metal-
loproteinases and its cleavage plays an important role in
tumor progression and can be used as a surrogate diagnostic
marker for in vivo MMP activity.
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Introduction
During cancer growth, tumor cells interact with the
surrounding environment. Mounting evidence now suggests
that the cancer cell and its microenvironment profoundly
influence each other and that a dynamic interaction occurs
between the two. The tumor microenvironment consists of
a variety of cell types, parts of the blood and lymphatic
systems and is rich in growth factors and enzymes, which
provide a readily available source of growth-promoting
signals to tumor cells. The influence between the environ-
ment and tumor cells is bi-directional. The microenviron-
ment permits the tumor cells to grow and spread, while
giving access to therapeutic agents and/or developing
resistance to cancer treatments. Non-cancerous adjoining
cells or the stromal cells in the microenvironment often take
on atypical characteristics and exert a profound influence
on a cancer cell's ability to develop into a tumor. It is not
yet established whether these neighboring cells lose their
tumor suppressing properties or whether they acquire
growth promoting properties or both. Expression and
release of many proteins from inflammatory and cancer
cells in the tumor microenvironment activates the signaling
cascades that regulate processes like tumor cell migration,
invasion, angiogenesis, apoptosis and metastasis. Certain
families of cell adhesion proteins like integrins, cadherins
and lectins have received extensive attention in the last few
decades. Lectins are non-enzymatic proteins present in
plants and animals, which specifically bind to carbohydrate
structures and play an important role in cell recognition.
In this review we have focused on a member of the lectin
family, galectin-3, which binds and interacts with a number
of glyco-conjugates in the intra- and extra-cellular environ-
ment and regulates many biological functions and signaling
pathways in normal and cancer cells.
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Galectin-3 is a ∼31 kDa unique chimeric gene product
belonging to the family of non-integrin β-galactoside
binding lectins with related amino acid sequences. Galec-
tin-3 is ubiquitously expressed in human adults, but the level
of expression varies by origin of the tissue. It is widely
expressed in epithelial and immune cells, such as gastric
mucosa, colon mucosa, mammary epithelium, prostate
epithelium, monocytes, and macrophages [reviewed in 1].
During the first trimester of human embryogenesis, the
expression of galectin-3 is restricted to epithelia, such as the
skin, epithelial lining of the digestive and respiratory tract,
urothelium and excretory tubes of the kidney, the myocar-
dial cells, the peripheral and preossifying hypertrophic
chondrocytes, as well as in notochord and the liver [2, 3].
Galectin-3 consists of three structural domains, each
associated with at least one specific function: (a) a NH2
terminal domain containing a serine phosphorylation site,
which is important in regulating its cellular signaling; (b) a
collagen-α-like sequence cleavable by matrix metallopro-
teinases; and (c) a COOH terminal containing a single
carbohydrate-recognition domain (CRD) and the NWGR
anti-death motif. Galectin-3 is mainly a cytosolic protein,
but can easily traverse the intracellular and plasma
membranes to translocate into the nucleus, mitochondria
or get externalized. This suggests that galectin-3 is a
shuttling protein and may have multiple functions accord-
ingly [4–6]. Galectin-3 is expressed in a variety of tumors.
The intensity of expression and localization depends on
tumor progression, invasiveness and metastatic potential.
Galectin-3 translocates to the perinuclear membrane in breast
cancer cells following a variety of apoptotic stimuli such as
cisplatin,staurosporine,orserum withdrawal [7–9]. In human
breast carcinoma, nuclear staining of galectin-3 was corre-
lated to the lobular type of invasive carcinoma, while tumor
stromal expression to high-grade malignancy [10, 11].
Sanjuan et al. [12] reported an increased cytoplasmic
expression of galectin-3 in more advanced stages of
colorectal cancer. Over-expression of galectin-3 in the
cytoplasm in human prostate cancer can promote its anti-
apoptotic activity as well as increase cell proliferation, tumor
growth, invasion, and angiogenesis while galectin-3 expres-
sion in the nucleus decreases cell proliferation [13]. The
enhanced expression of galectin-3 in the cytoplasm was
associated with a decreased disease-free survival of tongue
cancer patients [14].
Galectin-3 lacks the classical secretion signal sequence
and does not pass through the standard ER/Golgi pathway
[15]. Still it can be transported into the extracellular milieu
via a non-classical pathway [16]. There is ample evidence
to confirm its presence on the cell surface, in the
conditioned medium of some cell lines, in the extracellular
matrix and in the biological fluids and sera. It has been
shown that the NH2 terminal domain of galectin-3 is
critical for its secretion and is the driving force that
localizes it in the secretory vesicles [17]. Lukyanov et al.
[18] demonstrated the ability of galectin-3 to cross the lipid
bilayer of large unilamellar vesicles, suggesting that the
lectin has yet an unknown novel sequence that enables it to
traverse lipid membranes. Cells differ widely in their
capacity to secrete galectin-3. While J774.2 macrophage
cells secrete 30–45% of their galectin pool [19], BHK and
MDCK cells export 10–15% [20, 21] and WEHI-3 mouse
macrophages secrete a very small percentage of galectin-3
in the conditioned medium [19]. The exact mechanism of
galectin-3 secretion is not yet known. Hugh's group
proposed a vesicular release of galectin-3 from the cells
[20–23], while another pathway implicating galectin-3 to be
a component of the exosomes secreted by dendritic cells
was proposed by Thery et al. [24]. Recently, it was
demonstrated that galectin-3 is secreted and taken up by
the cells using a mechano-transduction mechanism [25].
Detached and spherical cells secrete galectin-3 in a
constitutive manner while attached and spreading cells take
up galectin-3 from the conditioned medium [25]. This
group also suggested that fetuin could act as a trigger for
the release of galectin-3 from the cells [26]. Once the
vesicles containing galectin-3 are exported outside of the
cell, galectin-3 is released into the extracellular matrix,
where it can interact with a myriad of partners regulating a
number of biological functions. The focus of this review is
on the biological functions regulated by extracellular
galectin-3 and their implication in cancer progression.
Role of Galectin-3 in Cell–Matrix and Cell–Cell
Interactions
The biological activities of galectin-3 in the extra-cellular
compartment mainly involve its interactions with various
β-galactoside containing glycans via its carbohydrate
recognition domain (CRD). The interaction of galectin-3
or its CRD with carbohydrate ligands is accompanied by a
conformational change [27] and rearrangement of the
backbone loops near the binding site [28]. Mazurek et al.
[29] demonstrated that the phosphorylation at Ser
6 of
galectin-3 strongly affects its sugar binding affinity, thus it
was proposed to be an “on/off” switch of its downstream
biological effects. There are numerous structurally and
functionally diverse biological ligands of galectin-3, some
of which have been well characterized. Exogenously added
galectin-3 promoted the adhesion of polymorphonuclear
neutrophils (PMN) to laminin-coated plastic in a carbohy-
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amino-terminal region was important for this adhesion [30].
Galectin-3 was shown to bind to glycosylated components
of extracellular matrix like laminin [30, 31] and fibronectin
[32], as well as hensin [33], elastin [34], collagen IV [34]
and tenascin-C and -R [35]. Galectin-3 was essential for
rapid adhesion of galectin-3 expressing BT-549 cells to
laminin and collagen, but not to fibronectin [36]. Likewise,
galectin-3 transfected Evsa-T human breast cancer cells
showed a higher adhesion to laminin, fibronectin and
vitronectin-coated plastic compared to the parental cells
[37]. Similarly, normal fibroblasts engineered to over-
express galectin-3 have also been shown to reorganize the
actin microfilaments in order to spread [38]. The inter-
actions of galectin-3 with lysosomal membrane glycopro-
teins Lamp-1 and -2 [39], carcinoembryonic antigen [40]
and colon cancer mucin [41] were suggested to be involved
in adhesion of cancer cells to extra-cellular matrix. In
addition, another class of cell adhesion proteins, integrins
(α1β1[ 34], and αMβ1[ 39]) were shown to be galectin-3
receptors. Galectin-3 transfected cells showed higher levels
of α6β1i n t e g r i n[ 42]. Regulation of α4β7i n t e g r i n
expression by galectin-3 was also reported [37]. Galectin-
3 was involved in the endocytosis of β1 integrins (CD29)
from the cell surface to intracellular vesicles via the
caveolae pathway [43]. Negative modulation of cell
adhesion to ECM proteins by galectin-3 has also been well
documented. For instance, high levels of galectin-3 on the
cell surface down-regulated cellular adhesion to ECM
proteins in a dose dependent manner. This effect was
abrogated in the presence of lactose [36]. The binding of
galectin-3 expressing SCM 153 human breast cancer cells,
A2058 and A375 melanoma cells to laminin was indepen-
dent of lactose or anti-gal-3 mAb inhibition [31, 44].
Although galectin-3 possesses only one CRD, it exhibits
bi-/multivalent binding properties [45, 46]. Both the carbo-
hydrate recognition and N-terminal domains were shown to
be involved in formation of galectin-3 multimers [47, 48].
Dimer or multimer formation of galectin-3 is implicated in
aggregation of tumor cells in the circulation during metas-
tasis by mediating homotypic cell adhesion via bridging with
branched, soluble complementary glycoconjugates [49]. This
spontaneous carcinoma cell homotypic aggregation was
shown to be mediated, in part, by the interactions between
cell surface Thomsen–Friedenreich glycoantigen (TFAg) and
galectin-3 [50, 51]. Grassadonia et al. [52] on the other hand,
demonstrated that the association of galectin-3 with 90K/
Mac-2BP in the extracellular matrix was responsible for the
homotypic aggregation. Galectin-3 mediates CD98 dimer-
ization by binding to the heavy chain of CD98, present on
human and mouse monocytes/macrophages and on activated
T cells, which in turn can promote integrin activation [39,
53]. Galectin-3 is also involved with heterotypic cell–cell
interactions. It promotes the adhesion of breast cancer cells
MDA-MB-435 to HUVEC [54] and endothelium, which was
inhibited by TFAg specific peptide [51]. Similarly, galectin-3
expressed on endothelial cells could interact with ligands on
the cell surface of carcinoma cells. For example, binding of
EC to galectin-3 null PC3 human prostate carcinoma cells
could be inhibited by anti-gal-3 mAbs [55]. Similarly, anti-
galectin-3 mAb inhibited the MDA-MB-435 cells rolling and
adhesion to HUVEC under flow conditions [56]. Galectin-3
expression was markedly enhanced in the plasma membrane
of EC after PMN adhesion, suggesting its importance in
PMN/EC interactions [57]. Krishnan et al. [58]d e m o n s t r a t e d
that galectin-3 constitutively expressed on the lung vascular
EC surfaces plays a key role in the adhesion of circulating
B16F10 murine melanoma cells to lungs. A significant role
of galectin-3 in cell–cell adhesion was also demonstrated by
specific inhibitors. Modified citrus pectin, a carbohydrate
ligand for galectin-3 inhibited galectin-3 mediated homo-
typic as well as heterotypic aggregation [59, 60]. In addition,
two small peptides that specifically bind to galectin-3 CRD,
interfered with rolling and stable adhesion of human breast
carcinoma cells to bone marrow EC and dramatically
reduced homotypic cell aggregation [61].
Role of Galectin-3 in Cell Migration, Chemotaxis
and Cell Activation
There is enough experimental evidence to suggest that
galectin-3 can trigger signal transduction cascades by cross-
linking with the glycan parts of the surface glyco-
conjugates, which in turn activate numerous biochemical
pathways in the cells, leading to the activation of various
cell types. For example, galectin-3 was shown to induce
endothelial cell morphogenesis and angiogenesis in vitro
and in vivo [54]. In addition, NG2, a transmembrane
chondroitin sulfate proteoglycan, was shown to mediate the
induction of endothelial cell motility and multicellular
network formation in vitro and the stimulation of corneal
angiogenesis in vivo by forming the NG2–galectin-3–α3β1
integrin complex, suggesting a mechanism by which
galectin-3 may induce angiogenesis [62]. The extra-cellular
galectin-3 also acts as a chemoattractant for monocytes and
macrophages, as well as alveolar macrophages [63]. By in
vivo and in vitro studies it was shown that higher
concentrations of galectin-3 (1 μM) are necessary for
chemotactic effects, while lower concentrations (10–
100 nM) induce increased non-directional cell movements
(chemokinesis). Chemotactic, but not chemokinetic activity
of galectin-3 was mediated by a pertussis toxin sensitive
pathway (G-protein-coupled cell surface receptors) [63].
Galectin-3 was involved with the migration of tumor
astrocytes and their invasion into the surrounding brain
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by the stroma, and reported as a modulator of thymocyte
migration by interfering with cell adhesion and promoting
subsequent detachment [65]. Similarly, galectin-3 trans-
fected breast (BT-549) and lung carcinoma (DLKP) cells
were more motile and invasive compared to the parental
cells [42, 66]. Over-expression of galectin-3 accompanied
by increased cell surface expression of α4β7 integrins,
caused enhanced adhesion to ECM glycoproteins as well as
increased invasiveness and spread [37]. At low concen-
trations galectin-3 stimulated cell spreading and motility in
β 1,6-acetylglucosaminyltransferase V (Mgat5) +/+ tumor
cells plated on a fibronectin substrate [67]. Some of the
exceptions are decreased motility of HCT-15, LoVo and
CoLo 201 human colon cancer cells on a Matrigel coated
surface by over-expression of galectin-3 [68], and an
increased motility in human glioblastoma U373 cells upon
down regulation of galectin-3 [69].
Galectin-3 was found to be over-expressed in TPA
induced differentiation of the human promyelocytic leuke-
mia cell line HL-60 to macrophages [70]. It potentiates
lipopolysaccharide (LPS)-induced production of interleu-
kin-1 (IL-1) [71] and triggers the production of superoxide
anion by human peripheral blood monocytes [72] and
neutrophils [73]. Presence of galectin-3 could induce a
respiratory burst in human peripheral blood neutrophils
after LPS exposure [74] paralleled by an increased binding
of galectin-3 to the surface of the cells, possibly through
functional receptors of galectin-3 in neutrophils CD66a and
CD66b [75]. It was recently shown that galectin-3 increases
phagocytic activity and CD66 surface expression on human
neutrophils [76]. The exposure of human Jurkat T cells to
galectin-3 stimulates the production of IL-2 [77], and it also
acts as a mediator of IgE production in B lymphocytes in
atopic eczema/dermatitis syndrome [78]. Galectin-3 was
shown to activate cardiac fibroblasts [79] and was increased
in synovial fibroblasts from rheumatoid arthritis patients
after adhesion to cartilage oligomeric matrix protein [80].
Galectin-3 was also shown to cross link Mgat5-modified
N-glycans on EGF and TGF-β, and delaying their removal
by constitutive endocytosis. It was speculated that the
presence of extra-cellular galectin-3 can be a determining
factor for prolonged cell activation [81]. On the other hand,
the extra-cellular galectin-3 can act as a suppressor of cell
activation as suggested by findings that galectin-3 cross-
linking of Mgat5-modified N glycans on T cell receptors
(TCR) prevents uncontrolled activation of T cells [82].
Regulation of Apoptosis by Extracellular Galectin-3
In the last decade, the role of galectin-3 as an anti-apoptotic
molecule has been well established. It imparts resistance in
response to various apoptotic insults in a wide variety of
cells. Over-expression of galectin-3 in the human breast
carcinoma cell line BT-549, resulted in reduced apoptotic
death induced by cis-diamminedichloroplatinum (cisplatin),
nitric oxide, radiation and anoikis compared to the parental
or the control transfected cells [9, 83]. Galectin-3 trans-
fected Jurkat cells (T lymphoma cell) were found to be
more resistant to apoptosis induced by anti-Fas antibodies
or staurosporine (protein kinase inhibitor) compared to the
non-transfected control cells [84, 85]. Galectin-3 is not a
member of the Bcl-2 gene family, however, it shares several
significant structural properties with Bcl-2. Both proteins
are rich in proline, glycine, and alanine amino acid residues
in the N-terminal domain and contain the Asp-Trp-Gly-Arg
(NWGR) motif in the C-terminal domain [85, 86]. This
motif, designated as the anti-death motif, is found in the
BH-1 domain of Bcl-2 and is shown to be critical for the
anti-apoptotic function of this protein [87]. Even though
endogenously expressed galectin-3 induced resistance to
apoptosis, there is no experimental evidence to indicate that
addition of galectin-3 exogenously induces apoptosis
resistance in tumor cell lines of epithelial origin. However,
it was reported recently that extra-cellular galectin-3 can
induce apoptosis in human T cells including human
peripheral blood mononuclear cells (PBMCs) and activated
mouse T-cells [88]. This would imply that tumor cells
secrete galectin-3 as a defense against infiltrating T-cells to
enable them to survive and proliferate. Interestingly, the
apoptotic sensitivity to galectin-3 varied among the differ-
ent cell types of T-cell lymphoma cell lines. Based on the
receptor type, two major signaling pathways have been
reported for extrinsic apoptotic signals; one using the death
receptors Fas (apo-1/CD95) and the other using TRAIL
(TNF related apoptosis inducing ligand or Apo2-L) [89,
90]. Fas are glycosylated type-1 transmembrane receptors
that activate either mitochondria dependent or independent
signaling pathways in the T cells in response to ligand,
depending on the amount of active caspase-8 produced at
the death-inducing signaling complex (DISC) [91–94].
Analysis of two kinds of T cell lymphoma cell lines
exhibiting either mitochondia independent (type I) and
mitochondria dependent (type II) pathways showed that
major difference between them is the presence of endoge-
nous galectin-3. Galectin-3 was reported to be a binding
partner of CD95 and galectin-3-null type I T-cell lines like
Jurkat, CEM, and MOLT-4 cells that were significantly
more sensitive to apoptosis by exogenous galectin-3 than
the type II cells SKW6.4 and H9, which have very high
expression of endogenous galectin-3 [95]. It was suggested
that there may be a cross talk between the anti-apoptotic
activity of endogenous and pro-apoptotic activity of
exogenous galectin-3 and the apoptotic effect may be
caused from a balance between the two. In addition, when
46 P. Nangia-Makker et al.galectin-3 was over-expressed in type II CEM cells, there
was binding of galectin-3 to CD95 receptor and the cells
displayed type 1 signaling pathways [95].
There is no report on the effect of exogenously added
galectin-3onTRAILinducedapoptoticpathwaysinTcells,but
galectin-3 over-expressing BT-549 breast cancer cells showed
dephosphorylation of Akt in response to TRAIL-induced
cytotoxicity [96] through regulation of phosphatase and tensin
homologue deleted on chromosome 10 (PTEN) [97].
The galectin-3-sensitive T-cells Jurkat and CEM, both
expressCD29 and CD7on thecellsurface, whereas galectin-
3-insensitive cells like SKW6.4 and H9 express CD29 but
not CD7. Extracellular galectin-3 can bind to the CD29/CD7
complex, which triggers the activation of intracellular
apoptotic signaling toward the mitochondria inducing
cytochrome c release and caspase 3 activation [88].
Extracellular galectin-3 can also bind to the T-cell
receptor complex (TCR) through the polylactosamine
structure extended by N-acetylglucosaminyltransferase V
(GnT-V) and form clustering followed by down-regulation of
T-cellactivity[82]. In addition, CD98, which is implicated in
the regulation of cell adhesion, growth and apoptosis, is a
galectin-3 binding partner found on the surface of T-cells
[53]. These results indicate that extra-cellular galectin-3
might not be an anti-apoptotic molecule by itself, but there is
the possibility that its interaction with a glycoconjugate
binding partner on the cell surface could protect cell viability
and anti-apoptotic activity in some cells.
Regulation of Angiogenesis and Tumor Progression
by Galectin-3
It was reported that secreted galectin-3 can induce
endothelial cell morphogenesis in vitro and angiogenesis
in vivo [54]. Binding of galectin-3 to the endothelial cell
surface is dependent on its carbohydrate recognition
domain as binding is specifically inhibited by a competitive
disaccharide lactose and polysaccharide modified citrus
pectin (MCP) [60]. In addition, the induction of endothelial
cell motility and multicellular network formation in vitro and
the stimulation of corneal angiogenesis in vivo provoked by
NG2, a transmembrane chondroitin sulfate proteoglycan,
was shown to be mediated by formation of NG2–galectin-
3–α3β1 integrin complex, suggesting a mechanism by
which galectin-3 may induce angiogenesis [62]. Using a
three-dimensional co-culture system of in vitro angiogene-
sis Shekhar et al. [10] demonstrated that galectin-3 is
important for the stabilization of the epithelial and
endothelial interactive network, as immuno-neutralization
with anti-galectin-3 antibodies abolished these interactions.
Over-expression of galectin-3 in transfected clones of
LNCaP, a galectin-3-negative human prostate cancer cell
line, induced in vivo tumor growth and angiogenesis [13].
Inhibitory studies were used to demonstrate significance of
galectin-3 during angiogenesis. Three novel low molecular
weight synthetic lactulose amines (SLA): N-lactulose-octa-
methylenediamine (LDO), N,N′-dilactulose-octamethylenedi-
amine (D-LDO), and N,N′-dilactulose-dodecamethylene
diamine (D-LDD) exhibiting differential ability to inhibit
binding of galectin-3 to the highly glycosylated protein 90K,
demonstrated selective regulatory effect in different events
linked to endothelial cell morphogenesis and angiogenesis
[98]. In addition, oral supplementation of modified citrus
pectin, a high pH and temperature modified hydrolysis
product of citrus pectin to nude mice showed reduced
metastatic and angiogenic potential in breast cancer cells
MDA-MB-435 [60].
Cleavage of Galectin-3 by MMPs In Vitro and In Vivo
Galectin-3 has a unique chimeric structure containing a
domain of Pro-Gly-Tyr tandem repeats of ∼110 amino acids
which connects the N-terminal to the C terminal. This α
collagen-like domain is susceptible to cleavage by matrix
metalloproteinases. Exhaustive bacterial collagenase degra-
dation of both the murine and human recombinant
homologues of galectin-3 generated a carboxy-terminal
polypeptide capable of maintaining the sugar-binding
properties of the cleaved molecule [27, 99–101]. Cleavage
of human recombinant galectin-3 by human MMPs was
first reported by Ochieng et al. [102], the cleavage site was
identified at the Ala
62-Tyr
63 bond resulting in a ∼22 and a
∼9 kDa product. These authors also showed that after
incubation with APMA activated MMP-2, cell surface
expression of galectin-3 was reduced indicating that cell
surface galectin-3 may also be cleaved by MMPs [102]. It
was later demonstrated that the ∼22 kDa cleaved product
lacks the capacity to hemagglutinate fixed red blood cells
and has reduced capacity to self-associate compared to the
intact galectin-3 [100]. In addition, cleavage of galectin-3
by metalloproteinases drastically improves its binding
interactions to laminin [100] and to endothelial cells
(HUVEC) [10]. It was postulated that cleavage of galec-
tin-3 by metalloproteinases results in an alteration of the
CRD culminating in higher affinity to glycans and reducing
the self association of the molecule thereby abrogating the
biological properties dependent on such associations or
homodimerization [100]. Shekhar et al. [10] detected
additional bands of ∼27 and ∼22 kDa in the conditioned
medium from the three-dimensional co-cultures of endo-
thelial and epithelial cells. These co-cultures also showed
extensive collagenolytic activity. Their results indicated that
MMPs may cleave galectin-3 in the extracellular milieu. It
has been well established that MMPs are synthesized as
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cleavage of the propeptide domain after secretion [103].
The surface [102] or secreted [10] galectin-3 could be
cleavedbyextracellularMMPs.InanotherstudybyJohnetal.
[104] treatment with a NH2 terminally truncated form of
galectin-3 showed reduced tumor growth and metastasis of
MDA-MB-435 cells compared with the control group. These
authors concluded that truncated protein effectively competes
with intracellular and extracellular galectin-3 and inhibits its
hemophilic cross-linking and other types of protein–protein
interactions. To analyze the biological significance of
galectin-3 cleavage by MMPs, mutations were constructed
at and around the MMP cleavage site Ala
62-Tyr
63.T h e
results showed that A to C mutation at position 191 leading
to substitution of His
64 with Pro confers resistance to
cleavage by MMP-2 and -9 at that position. Both the
galectin-3 variants (H
64 and P
64) were stably expressed in the
galectin-3 null breast cancer cell line BT-549. The cells
harboring a P
64 variant showed an altered morphology,
reduced chemotaxis and chemo-invasion, abrogated resis-
tance to apoptosis, reduced tumor forming potential and
angiogenesis (the functions regulated by extracellular galec-
tin-3) as compared to the H
64 galectin-3 harboring cells. On
the other hand, the functions regulated by intracellular
galectin-3, like cell proliferation and anchorage independent
growth efficiency remained unchanged [105]. These results
suggested that the extra-cellular cleavage of secreted
galectin-3 H
64 by MMPs may play a significant role during
tumor development/progression. To analyze if this cleavage
could also be observed in vivo, tissue array consisting of the
progressive stages of breast cancer was stained with galectin-
3 monoclonal and polyclonal antibodies to selectively
differentiate between the intact and cleaved galectin-3. The
results showed that in the normal breast ducts no cleavage
could be observed. In lobular hyperplasia the intact protein
could be detected on the lobular side of the ducts, whereas the
cleaved protein could be detected adjacent to the stroma. In
ductal carcinoma in situ (DCIS), the full-length protein could
be detected in a few epithelial cells, while the cleaved protein
couldbeseeninthestroma.Intheinfilteratingcarcinomas,the
invasive cell clusters and the surrounding stroma were
positive for cleaved protein indicating that cleavage of
galectin-3 is vital for the progression of breast cancer
(unpublished data). A mouse model of human DCIS of the
breast was utilized in order to analyze whether these results
could be translated as a diagnostic tool to identify the activity
of MMPs in vivo. Part of the xenograft was fresh frozen to
perform insituzymography,while the other partwas paraffin-
embedded and stained with galectin-3 monoclonal and
polyclonal antibodies. The results show an overlap between
the MMP activitiesby insitu zymographyand the cleavage of
galectin-3 indicating that this differential staining could
indeed be used as a surrogate diagnostic marker for MMP
activity in the developing breast tumor [105].
Fig. 1 Extracellular functions
mediated by galectin-3. The se-
creted galectin-3 potentiates an-
giogenesis by facilitating
migration, chemotaxis and mor-
phogenesis of endothelial cells.
It also induces T cell apoptosis.
The cell surface proteinis involved
with homotypic and heterotypic
cell aggregation and invasion
leading to metastasis. Extracellular
galectin-3 cross-links cell surface
glycol-conjugates, form dimers
and multimers, and delivers sig-
nals inside the cell. The ∼22 kDa
fragment of MMP cleaved
galectin-3 binds to the glycan
receptors more efficiently than the
intact protein, the functions of
smaller fragments are as yet
unknown
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Galectin-3 contributes to tumor progression through many
different mechanisms. The biological roles of galectin-3 were
initially attributed to its carbohydrate-binding activity. It was
thought to play a role largely in cell adhesion leading to
homotypic aggregation of tumor cell embolus in the blood
circulation. During the past decade a whole new spectrum of
itsfunctions,unrelatedtolectinactivity,hasbeenrevealedand
a plethora of physiological functions in the extracellular
compartment have been assigned to it and more are yet to be
discovered. Extracellular galectin-3 was found to be involved
with cell–cell and cell–matrix adhesions, chemotaxis, chemo-
invasion, apoptosis of the immune cells, angiogenesis and
metastasis (Fig. 1). An under explored function of the
extracellular galectin-3 is its cleavage by MMPs, which
seems to play an important role in tumor progression. Cells
harboring cleavage resistant galectin-3 showed reduced
tumor growth, angiogenesis and resistance to apoptosis
compared to the cleavage sensitive galectin-3. Cleavage of
galectin-3 was observed increasingly with the progressive
stages of breast cancer emphasizing its significance during
tumor progression. It is yet to be established whether cleaved
galectin-3 fragments follow the same signaling pathways as
the full-length galectin-3. It was demonstrated that the larger
22 kDa fragment retained its carbohydrate-binding proper-
ties, albeit it binds to the glycan receptors with a higher
efficiency. The fate of the smaller fragments is as yet
unknown. Whether they bind to the same receptors as the
full-length protein or different ones; whether they are
internalized by the cells or remain in the extracellular matrix
and modulate the signaling pathways; what are the signaling
pathways regulated by these fragments are some of the
questions that still need to be answered.
Although the exact role of the galectin-3 cleavage in
tumor progression is yet to be determined, its clinical
significance as a surrogate diagnostic marker for the
activity of MMPs in the tissues has been proposed. It is
expected that identification and analysis of galectin-3
cleavage in cancer can be used as a tool for validation of
the effectiveness of MMP inhibitor therapy.
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